Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Deals & Financings

VC fundings, mergers and acquisitions, and other financing events...

Hansoh Acquires China Rights to Osteoarthritis Therapy in Deal Worth $63 Million-Plus

Zai Lab In-Licenses Cervical Cancer ADC from Seagen for $30 Million Upfront

Huisheng Biopharma Closes $70 Million Round for Diabetes Drug Portfolio

CASI Divests 12% Stake in Juventas, its CAR-T Partner, for $34 Million

Sino Biopharm Signs $307 Million Deal with Inventiva for NASH Therapy

ChinaBio Event
Beijing and Digital
November 8-11, 2022
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
July 27-31, 2022